Travis Tanner is Executive Director for China at the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents leading biopharmaceutical research companies. For decades, PhRMA member companies have pushed the boundaries of science, investing in new technology, research, treatments and vaccines that help advance medicines for patients everywhere. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures. PhRMA works to advance policies that encourage the discovery of important new medicines and increase patient access to innovative medicines.
Mr. Tanner is based in PhRMA’s China office, leading government, policy and public engagement for PhRMA in China. He also serves as Vice Chair of the Board of Governors for the American Chamber of Commerce in China (AmCham China).
Mr. Tanner is a trusted China advisor with more than 25 years’ experience building bridges between Chinese and U.S. corporate, government, academic and non-profit communities. Before joining PhRMA, he was President of GreenPoint Group and Senior Managing Director at Ankura, where he remains a Senior Advisor. He has held leadership and research positions at the U.S.-China Strong Foundation, the National Bureau of Asian Research (NBR), the Nixon Center and the Peterson Institute for International Economics. He is the author, contributing author or coeditor of numerous publications on the strategic, economic and political dimensions of the U.S.-China relationship.
Mr. Tanner serves as a senior advisor to NBR, is a Tsinghua University Schwarzman College industry mentor and a member of the National Committee on U.S.-China Relations. He holds a BA in Chinese language and literature from the University of Utah and an MA from the Johns Hopkins University School of Advanced International Studies and the Hopkins-Nanjing Center.